Olie, R. H.
van der Meijden, P. E. J.
Vries, M. J. A.
Veenstra, L.
van ‘t Hof, A. W. J.
ten Berg, J. M.
Henskens, Y. M. C.
ten Cate, H.
Article History
Accepted: 18 June 2021
First Online: 1 September 2021
Declarations
:
: R.H. Olie reports advisory and speakers’ fees from Leo Pharma, Portola and Bayer, and travel grants form Sanofi, all outside the submitted work. A.W.J. van ‘t Hof reports grants from Medtronic, Abbott and Boehringer Ingelheim, and grants and speakers fees from AstraZeneca, outside the submitted work. J.M. ten Berg reports advisory, consulting and speakers’ fees from AstraZeneca, Eli Lilly, Daiichi Sankyo, The Medicines Company, Accumetrics, Boehringer Ingelheim, BMS, Pfizer, Bayer and Ferrer, and received institutional research grants from ZonMw and AstraZeneca, all outside the submitted work. H. ten Cate reports research support from Bayer and Pfizer/BMS, participated in advisory boards for Bayer, Pfizer/BMS and Daiichi Sankyo, grants from Dutch Heart Foundation (CVON, CONTRAST), Eu-Marie Curie ITN (TAPAS, TICARDIO) and Regmed XB. HC is consultant for Alveron, shareholder in Coagulation Profile and is unpaid chairman of the Federation of Dutch Anticoagulation Clinics, all outside the submitted work. P.E.J. van der Meijden, L. Veenstra, Y.M.C. Henskens and M.J.A. Vries declare that they have no competing interests.
: Approval for the observational cohort was obtained by the medical ethics committee of the Maastricht University Medical Centre (NL38767.068.11, METC number 11-2-096).